🇺🇸 Xeris Pharmaceuticals
Forum topic · XERS · Company page: financials, ownership and filings
Join the discussion on Xeris Pharmaceuticals
Loading…
Results announced on 5 November 2026
Xeris Pharmaceuticals announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $107 million (up 44% from a year earlier) and net income of $11 million (up 1721% from a year earlier).
Insider trading in October 2026
Directors and officers of Xeris Pharmaceuticals reported open-market trades for October 2026 (SEC Forms 4 and 5): 3 insiders sold shares worth about $344,949 in 3 trades.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 159 funds hold $301 million
159 mutual funds in 1 country hold shares of Xeris Pharmaceuticals worth $301 million, about 21.4% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 103 funds added shares and 33 sold; on balance they bought $57 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.